Condition

Stage IV Rectal Cancer

ClinicalTrials.gov condition label

Clinical trials13
Recruiting0
Common interventions25
Lead sponsors shown4

Clinical trials

13 shown
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor SitesNCT04267575 · 2019-07-30
UNKNOWN
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerNCT03154190 · 2017-08-08
COMPLETED
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsNCT01233505 · 2010-10-01
TERMINATED
RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsNCT01158274 · 2010-06-01
COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerNCT01037790 · 2009-10-01
COMPLETED
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerNCT00397384 · 2007-01-01
COMPLETED
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNCT00101348 · 2005-01-01
COMPLETED
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal CancerNCT00088933 · 2004-06-01
TERMINATED
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerNCT00087191 · 2004-05-01
TERMINATED
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)NCT00031681 · 2001-12-01
COMPLETED
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionNCT00030498 · 2001-12-01
COMPLETED
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerNCT00028496 · 2001-11-01
COMPLETED
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNCT00004074 · 1999-08-01
COMPLETED

Common interventions

laboratory biomarker analysisOTHER6erlotinib hydrochlorideDRUG3capecitabineDRUG2pharmacological studyOTHER27-hydroxystaurosporineDRUG1ABI-007/carboplatin/trastuzumabBIOLOGICAL1Best PracticeOTHER1bevacizumabBIOLOGICAL1Canady Helios Cold Plasma ScalpelDEVICE1cetuximabBIOLOGICAL1cetuximabDRUG1diagnostic laboratory biomarker analysisOTHER1docetaxelDRUG1EF5DRUG1gamma-secretase/Notch signalling pathway inhibitor RO4929097DRUG1irinotecan hydrochlorideDRUG1motexafin lutetiumDRUG1oxaliplatinDRUG1PD-0332991DRUG1recombinant fowlpox GM-CSF vaccine adjuvantBIOLOGICAL1recombinant fowlpox-CEA(6D)/TRICOM vaccineBIOLOGICAL1recombinant fowlpox-CEA(6D)/TRICOM vaccineDRUG1recombinant interleukin-12BIOLOGICAL1recombinant vaccinia-CEA(6D)-TRICOM vaccineDRUG1sargramostimBIOLOGICAL1

Trial status mix

COMPLETED9
TERMINATED3
UNKNOWN1

Phase mix

PHASE19
NA3
PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.